Home World News FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic... World News FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer By Ogkologos - September 23, 2026 248 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Pharmacy services are an untapped resource in tackling nation’s major health... July 12, 2022 Experts Urge to Remove Care Inequalities for Adolescents and Young Adults... April 8, 2021 Women and girls in science: We won’t stop pushing for progress February 11, 2023 Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... September 7, 2021 Load more HOT NEWS 5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His... EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms